The TAME trial, a phase III clinical trial, aimed to investigate whether targeted therapeutic mild hypercapnia (TTMH) could improve neurological outcomes at 6 months for resuscitated cardiac arrest patients in comparison to standard care (targeted normocapnia). This study holds significant importance in exploring potential advancements in post-cardiac arrest treatment strategies.

We have another important milestone to celebrate! On the 17th of February 2023, the SNAP (Staphylococcus Aureus Network Adaptive Platform) Trial reached its one-year anniversary.